Azelastine hydrochloride (AZE) is an anti-allergic drug that inhibits the release of various chemical mediators from mast cells. We compared the immunosuppressive effects of AZE and FK-S06 in vivo and in vitro. Topical application of AZE strongly inhibited the efferent phase of contact hypersensitivity, as did application of FK-S06. In in vitro experiments, we found that 1) the suppression by AZE on interleukin (IL)-2 production from splenic T cells was partial and considerably large amounts of IL-2 were still produced, even in the presence of 10-5 M of AZE, which was in sharp contrast to the observed marked inhibition of [3H]_ TdR incorporation; 2) AZE significantly inhibited the phorbol myristate acetate-induced IL-2 responsiveness; 3) AZE did not inhibit the IL-2 receptor a expression of activated T cells; and 4) the significant inhibitory action was still observed even when AZE was added at 48 h after the initiation of culture. In A zelastine hydrochloride (AZE; C22H24ClN3o' HCI, MW = 418.37) (Fig 1) is an anti-allergic drug that inhibits allergic bronchospasms and passive cutaneous anaphylaxis in rats and guinea pigs [1, 2] . AZE has potent histamine HI-receptor -blocking properties [1,3]' AZE als.o exerts strong inhi~itory effect.s on .the release of chemical mediators such as leukotnenes and hlstamme from mast cell [2,4]' In addition, AZE possesses leukotriene and serotonin receptor-blocking activities [1, 2] . Based on these findings, AZE is now used widely in Japan as an effective and long-acting anti-allergic drug for the treatment of atopic disorders such as asthma, allergic rhinitis, and atopic dermatitis. In the screening of the immunomodulatory roles of various agents, we found that AZE had potent immunosuppressive effects. The present study was undertaken first to investigate whether the topical application of AZE has a capacity to inhibit contact hypersensitivity itl vivo, and second, to characterize the immunosuppressive activity of AZE in vitro, in comparison with the well-characterized immunosuppressant FK-S06. The results show that topical application of AZE strongly inhibits the efferent phase of contact hypersensitivity, and that AZE exerts its Manuscript
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regard to FK-506, we found that 1) FK-506 completely blocked the production of IL-2; 2) exogeneous IL-2 consistently restored the FK-506-induced inhibition; 3) FK-506 affected the phorbol myristate acetate -induced IL-2 responsiveness very little, if any; and 4) the significant suppression was observed only when FK-506 was added within 24 h after the initiation of culture. Thus, AZE exerts its ill vitro immunosuppressive activity preferentially by interfering with the IL-2 responsiveness, with partial inhibition of IL-2 production. Conversely, FK-506 acts as a strong inhibitor of IL-2 production without a prominent effect on IL-2 responsiveness. immunosuppressive activity preferentially by interfering with interleukin (IL-2) responsiveness, with partial inhibition of IL-2 production, which is distinct from the results observed with FK-S06.
MATERIALS AND METHODS
Animals C3H/HeN and Balb/c mice were obtained from the Shizuoka Agricultural Cooperative Association for Laboratory Animals, Hamamatu, Japan.
Reagents AZE was obtained from the Eisai Co., Tokyo, J apan. FK-506 was obtained from the Fujisawa Pharmaceutical Co., Osaka, Japan.
Concanava!!n A (Con A) and phorbol myristate acetate (PMA) were purchased from Sigma. lonomycm was purchased from Calbiochem, La Jolla, CA. Anti-IAk monoclonal antibody was obtained from culture supernatants of the 10.2.16 hybndoma (mouse IgG2b, American Type Culture Collection~ Rockville, ~D) . Fluorescein isothiocyanate (FITC) -conjugated antimUrIne mterleukm 2 (IL-2) receptor 0: monoclonal antibody (7D4, rat immuno~lobulin [Igl~) and FITC-c?njugated rat IgM were purchased from P~armmgen, San Diego, CA. Antl-Thy1.2 antibody (Rat IgG2b) was obtamed from Beckton Dlckmson, San Jose, CA. FITC-conjugated goat antimouse IgG was ~urchased from Cappel, West Chester, PA. FITC-conjugated sheep anti-rat IgG2b was purchased from The Binding Site, Blrmmgham, U .K. Munne recombinant interleukin 2(MrIL-2) was obtained from Genzyme, Cambridge, MA.
Effects of Drugs on Contact Hypersensitivity
In Vivo AZE and FK-506 were dissolved in 2: 1 dimethylsulfoxide (DMSO) : ethanol to a contraction of 3.3% (w/v, 0.079M) and 1 % (w/v, 0.012M), respectively. C3H mice were sensitized by the epicutaneous application of 1 00 jll of7% 2,4,6-trinitro-chlorobenzene (TNCB; ICN Pharmaceuticals, Inc., Plainview, NY) in 4 : 1 acetone: olive oil, as previously described [5] . Seven days 0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc.
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• HCl
Cl Azelastine : ['H_ TdR] Incorporation of Accessory Cell-Dependent T-Cell Stimulation Assay Complete medium used was RPMI 1640 supplemented with 10% fetal calf serum (Gibco, Grand Island, NY), 100 U /ml penicillin, 100 J.lg/ml streptomycin, and 0.25 J.lg/ml amphotericinB. AZE and FK-S06 were dissolved in DMSO at a concentration of 10-2 M and 10-3 M, respectively. These stock aliquots were used to prepare various concentrations of the agents in complete medium. The DMSO diluents were diluted in parallel to serve as solvent control.
Murine splenocytes (4 X 10 5 cells/well) were cultured with 5 J.lg/ml of Con A for 72 h in a 96-well flat-bottomed microculture plate in triplicate (total, 0.2 ml) with solvent control, AZE, or FK-506. Cultures were pulsed with 1 J.lCi of ['H]-TdR (ICN Biomedicals, Irvine, CA) for the last 16-18 h.
In the timecourse experiment, AZE, FK-506, or solvent control were added at 0,24, and 48 h after the initiation of culture and [3H]-TdR incorporation was assayed. Percentage inhibition was calculated according to the following formula: % inhibition _ cpm of culture with solvent control -cpm of culture with drug -cpm of culture with solvent control -cpm of background culture X 100 (%).
I'H-TdR] Incorporation of Accessory Cell-Independent T-Cell Stimulation Assay T cells were purified from splenocytes after they were passed over a nylon wool column and treated with anti-I-A antibody plus complement (6] . The resulting purified Tcells contained> 95% Thy-l +and < 0.2% Ia+ cells, as identified by immunofluorescence. T cells (1 X 10 5 cells/well) were stimulated with PMA (10 ng/ml) plus ionomycin (200 ng/ml) for 72 h in 96-well plates in triplicate (total, 0.2 ml/well) with solvent control, AZE, or FK-506. All cultures were pulsed with 1 J.lCi of (3H]_ TdR for the last 16 -18 h.
Restoration of the Drug-Induced Inhibition by MrIL-2 To examine the restorative activity of MrIL-2, 100 U/ml of MrIL-2 was added to the culture with AZE or FK-506, and T-cell proliferative response was assayed by ['HJ-TdR incorporation in accessory cell-dependent or -independent assay.
PMA-Induced IL-2 Responsiveness The purified T cells were activated with MrIL-2 (50 U /ml or 150 U/ml) in the presence ofPMA (10 ng/ml) for Figure 2 . Effects of AZE and Fk-S06 on the contact hypersensitivity itl vivo by topical application. C3H mice were sensitized epicutaneously with 7% TNCB and 7 d later ears were challanged with 20/11 of 1 % TNCB and ear swelling was measured. One hour before challanging, ears were applied with 30 J.ll of 3.3% AZE, 1 % FK-506, or diluent control (DMSO: ethanol = 2: 1).· P < 0.01.
72 h with or without drugs, and (3H]-TdR incorporation was assayed as described above.
IL-2 Production Assay Culture supernatants were collected at 24 h after the initiation of culture. The IL-2 -sensitive T-cell line CTLL (5 X 10' cells/well) was incubated with serially diluted culture supernatants for 24 h and pulsed with 1 J.lCi of (3H]_ TdR for the last 6 h, as described previously [7J. IL-2 production (U /ml) was quantitated from the positive control curve using MrIL-2. In this bioassay, neither AZE nor FK-506 had any effect on the proliferation of CTLL up to the diluted concentration examined.
Effects of Drugs on PMA-Induced IL-2 Receptor a Expression Purified T cells were activated by 10 nglml ofPMA with or without drugs for 24 h as described above, and were stained with FITC-conjugated anti -IL-2 receptor a antibody or control FlTC-conjugated rat IgM.
The stained T cells were analyzed using the EPICS Profile Analyzer, Coulter Corp.
Statistical Analysis The Student t test was used to compare results. A p value of less than 0.05 was considered to be significant.
RESULTS
Effects of AZE and FK-S06 on the Contact Hypersensitivity
In Vivo by Topical Application We first analyzed the effects of topical application of AZE on the contact hypersensitivity in vivo. We used FK-S06 as an effective drug control. The immunosuppressive activity of topical FK-S06 has been reported previously [8] . C3H mice were epicutaneously sensitized with 7% TNCB. Seven days later, 30 fll of either 3.3% (0.079 M) AZE, 1% (0.012 M) FK-S06, or diluent control was applied on the ear that was further painted with 1 % TNCB 1 h later. The immunosuppressive effect of AZE or FK-S06 was evaluated by measuring ear thickness. The single application of AZE or FK-506 strongly inhibited the ear swelling (Fig 2) . In three independent experiments the percentages of inhibition by AZE were 83.9%, 88.3%, and 100%, respectively.
Effects of AZE and FK-506 on [3H]-TdR Incorporation in
Accessory Cell-Dependent T-Cell Stimulation Assay W e examined the effects of AZE and FK-S06 on the viability of unstimulated splenocytes in vitro. The viability of unstimulated splenocytes was not affected significantly by AZE (up to 10-5 M) or FK-S06 (up to 10-8 M) after 72 h incubation when compared with solvent control or medium only (data not shown). We next examined the effects of AZE and FK-S06 on the proliferation of splenocytes stimulated with Con A. Both AZE and FK-506 dose-dependently inhibited the [3H]_ TdR incorporation of splenocytes (Fig 3) . Average SO% effective dose (ED50) of AZE was 3. Tirnecourse of AZE-or FK-S06-Induced Inhibition AZE, FK-506. or solvent control was added at 0, 24, or 48 h after the initiation of culture, and percent inhibition was compared in Con A -induced proliferation of splenocytes. The inhibitory activity of FK-S06 declined rapidly as the time added became later, whereas AZE still retained high inhibitory action even when added at 48 h later (percent inhibition by the addition of drugs at 0, 24, and 48 h later: AZE, 97%, 88%, 53.8%; FK-S06, 93.4%, 73.5%, 15.8%).
Effects of AZE and FK-506 on the IL-2 Production in Accessory Cell-Dependent T-Cell Stimulation Assay The splenocytes were stimulated with Con A in the presence of AZE, FK-S06, and solvent control, and IL-2 production was assayed. The effects of AZE and FK-S06 on the [3H]_ TdR incorporation were also examined at the same time. As shown in Table I , FK-S06 completely inhibited the IL-2 production at a concentration of 10-8 M. Although AZE .M) significantly inhibited IL-2 prod~ction, the inhibition was partial and large amounts of IL-2 were stdl secreted by Con A -stimulated splenocytes, even in the presence of AZE. In contrast, the inhibitory activity of AZE on the [3H]_ TdR incorporation was again as potent as that of FK-S06.
Restoration of the Immunoinhibitory Action of AZE and FK-S06 in the Accessory Cell-Dependent Assay We next investigated whether some exogeneous factor(s) could counteract the inhibitory activities of AZE or FK-S06. Because considerably large amounts of IL-2 were still produced even in the presence of AZE, whereas there was complete suppression of IL-2 production by FK-S06, we assumed that exogeneous IL-2 may counteract the inhibitory action ofFK-S06, but not that of AZE, This was the case, as shown in T able II. W e added MrIL-2 (100 U/ml) to the culture. and the restorative property of MrIL-2 was examined. MrIL-2 partially but significantly restored the FK-S06-but not the AZEinduced inhibition. (Table III) .
With regard to IL-2 production, FK-506 completel y abrogated the IL-2 production from T cells stimulated by PMA + ionomycin, whereas AZE showed only mild inhibitory activity on the IL-2 production.
Again, exo geneous MrIL-2 had no significant restorative activity on AZE-induced immunos uppression . However, FK-506 -induced immunosuppression was restored completely by the addition of MrIL-2 (Table III) . Compared w ith the accessory cell -dependent stimulation assay, the restorative activity ofMrIL-2 was much more prominent in the accessory cell -independent T -cell-stimulation assay, suggesting that FK-506 has some inhibitory activity not only for T cells but also for accessory cells, and that the restorative activity of MrIL-2 acts mainly on T cells .
Effects of AZE and FK-S06 on PMA-Induced IL-2 Responsiveness of Purified T Cells W e next examined the effects of AZE and FK-S06 on the PMA-induced IL-2 responsiveness of purified T cells (Table IV) . AZE strongly inhibited PMA-induced IL-2 responsiveness in either higher (150 U /ml) or lower (50 U/ml) concentrations of MrlL-2. On the contrary, FK-S06 affected the PMA-induced IL-2 responsiveness very little, if any, which was in sharp contrast to the marked inhibition of IL-2 production by FK-506. These data indicate that AZE exerts its immunosuppressive activity mainly by interfering w ith th e IL-2 responsiveness, whereas FK-S06 acts as a strong inhibitor of IL-2 production.
Effects of AZE and FK-506 on the IL-2 Receptor a (CD25)
Expression of Activated T Cells We next examined the effects of the drugs on IL-2 receptor a expression by use of activated T cells. Purified T cells were activated by 10 nglml ofPMA and the CD2S expression was compared in the presence or absence of the drugs.
Solvent control (DMSO) per se had a greater tendency to increase CD2S expression than did the control medium. However, neither AZE nor FK-S06 significantly affected the CD2S expression when compared to solvent control (Fig 4) . These data indicate that the AZE.induced inhibition of IL-2 responsiveness is likely to exist, irrespective of its receptor expression. • Splenocytes were activated by Con A with drugs or solvent control in the presence or absence of MrIL-2 (100 U/ml).
• ['H-TdR) incorporation (m ea" cpm).
dening reaction induced by contact hypersensitivity to dinitrofluorobenzene in pigs [8] . Hanada et al have described that topical application of 0.1-5% AZE solution significantly inhibited the ultraviolet B -induced erythematous reaction in guinea pigs [9] '
To know whether AZE has an ability to modulate the function of immunocompetent cells, we next compared the in vitro immunosuppressive effects of AZE and FK-506 using the accessory celldependent or -independent T-cell activation assay. We found that 1) AZE inhibited the [3H]-TdR incorporation in a dose-dependent manner; 2) the suppression of IL-2 production was partial and considerably large amounts of IL-2 were still produced, even in the presence of 10-5 M of AZE, which was in sharp contrast to the marked inhibition of[3H]-TdR incorporation; 3) AZE significantly inhibited the PMA-induced IL-2 responsiveness; 4) the inhibitory actio n was not restored by MrIL-2; 5) AZE did not inhibit the CD25 expression of T cells; and 6) the significant inhibitory action was still observed even when AZE was added at 48 h after the initiation of culture.
With regard to FK-506, the immunosuppressive mechanism(s) was likely to be due to the inhibition ofIL-2 production, because 1) FK-506 completely blocked the production ofIL-2; 2) exogeneous IL-2 consistently restored the FK-506-induced inhibition; 3) the significant suppression was observed only when FK-506 was added within 24 h after the initiation of culture; 4) FK-506 affected the PMA-induced IL-2 responsiveness very little, if any.
Thus our data demonstrate that AZE exerts its immunosuppressive activity preferentially by interfering with the IL-2 responsiveness with partial inhibition oflL-2 production, and conversely FK-506 acts as a strong inhibitor ofIL-2 production without prominent 'Mean U/ m!. J NO, not done.
effect on IL-2 responsiveness. The different immunosuppressive mechanism between AZE and FK-506 may explain the fact that AZE is still inhibitory, even at 48 h after the T-cell activation, whereas T-cell proliferation is induced by the engagement of the IL-2 receptor with already produced IL-2 by an autocrine mechanism. Our results on the immunosuppression by FK-506 are in good accordance with those reported previously [10, 11] .
Todoroki et at reported that AZE inhibited the antigen-specific IL-2 responsiveness of human peripheral blood mononuclear cells [12] . They reported that the adherent cell population was more susceptible to the inhibitory action by AZE. Further studies are necessary to clarify whether AZE has a capacity to modulate the function of antigen-presenting cells such as Langerhans cells. The cellular binding site or binding molecule for AZE is unclear.
Akagi et at reported the possibility that AZE may be internalized in the lipid bilayer of the cell membrane and stabilize the membraneassociated signal transduction using a dipalmitoylphosphatidylcholine liposome model [13, 14] . The membrane-stabilizing activity of AZE was further demonstrated by erythrocyte lysis assay. Suzaki et at showed that 3 X 10-6 M to 3 X 10-5 of AZE inhibited hypoosmotic lysis of red blood cells in a dose-dependent manner [15] . Because AZE did suppress IL-2 responsiveness without inhibiting the expression of IL-2 receptor a, AZE-induced inhibition of IL-2 responsiveness may be attributable to the uncharacterized membrane-stabilizing activity. Alternatively, AZE may possibly inhibit • Purified T cells were stimulated with PMA (10 ng/ml) plus MrlL-2 (50 V/ml or 150 U/rnI) and the inhibitoty effects of AZE or FK-506 were examined on ['H]-TdR incorporation. The restorative activity of MrlL-2 (100 U /ml) was also examined.
• Although AZE has distinct immunosuppressive activities itl vitro, a much higher dose is necessary for AZE (10-5 M) than for FK-506 (10-9 M). The therapeutical serum concentration of AZE after oral administration of 2 mg / d is only as high as 3 X 10-9 M. Even though the tissue level of AZE is reported to be 30 -40 times higher than serum level, 10-5 M of AZE seems to be far beyond the range of concentration obtained by systemic administration in clinical use. Therefore, we first assessed the effect of AZE on contact hypersensitivity by topical application where high local concentration of AZE would be expected. The strong inhibitory action of AZE on contact hypersensitivity suggested that the immunosuppressive activity shown in vitro may be operative in vivo. Further studies are necessary to know whether topical AZE also inhibits the afferent phase of contact hypersensitivity.
